Form 4: AnaptysBio Director Acquires Restricted Stock Units
Statement of Changes in Beneficial Ownership
AnaptysBio Director John Orwin acquired 6,030 restricted stock units, vesting fully on June 15, 2026.
Summary
- John Orwin, a Director at AnaptysBio, Inc., acquired 6,030 restricted stock units (RSUs) on June 15, 2026.
- These RSUs represent a contingent right to receive one share of AnaptysBio's common stock upon settlement.
- The RSUs are set to vest 100% on June 15, 2026, provided Mr. Orwin continues to provide service to the company on that date.
- The acquisition was made for no monetary consideration.
- Following this transaction, Mr. Orwin beneficially owns 16,695 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation and incentive mechanism for a director rather than a new strategic development or significant financial event.
Positives
- Director acquisition of stock units can signal confidence in the company's future prospects.
- The RSUs are fully vested on a specific future date, aligning the director's incentives with long-term company performance.
Risks
- The vesting of RSUs is contingent on continued service, meaning a departure before June 15, 2026, would result in forfeiture.
- The value of the acquired RSUs is directly tied to the future stock price performance of AnaptysBio.
Future Outlook
The restricted stock units are scheduled to vest in full on June 15, 2026, contingent upon the reporting person's continued service to the issuer.
Industry Context
StockSavvy.ai notes that insider transactions, such as this acquisition of RSUs by a director, are common in the biotechnology sector as a means to attract and retain key talent and align executive interests with shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | John Orwin has granted a power of attorney to Daniel Faga, Christopher Murphy, and Dave McKeon to execute Form 3, 4, or 5 reports on his behalf. | June 17, 2026 | Standard administrative procedure to facilitate SEC filings. |
Stakeholder Impact
- Shareholders: The acquisition of RSUs by a director may be interpreted as a positive signal of confidence in the company's future performance, potentially influencing investor sentiment.
- Employees: Standard compensation practice that aligns director incentives with company success.
- Management: Reinforces the alignment of interests between the board and executive leadership.
Next Steps
- Vesting of 6,030 restricted stock units on June 15, 2026, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 06/15/2026 | Earliest transaction date and RSU vesting date. |
| 06/17/2026 | Date of signature for the Form 4 filing. |
Keywords
AnaptysBio, Form 4, SEC Filing, Restricted Stock Units, RSU, Director, Beneficial Ownership, Stock Vesting, Insider Transaction, ANAB
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.